[1] 解士海,马鹏程.银屑病的生物治疗进展.国外医学皮肤性病学分册,2003,29:78-81
[2] 楚瑞琦,刘平,谭顺,等银屑病的免疫生物学治疗进展.中华皮肤科杂志,2003,36:174-175.
[3] 吴绍熙,郭宁如.银屑病治疗研究新进展.中华皮肤科杂志,2003,36:177-178.
[4] 郑敏.银屑病是细胞免疫介导性疾病?中华皮肤科杂志,2002,35 : 85-87
[5] LaDuca JR, Gaspari AA. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin, 2001, 19:617-635.
[6] Mahe E, Descamps V. Anti-TNF alpha in dermatology. Ann Der matol Venereol, 2002, 129: 1374-1379.
[7] Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid sparing experience using infliximab for Crohn's disease at a pedi atric inflammatory bowel disease center. Am J Gastroenterol, 2003, 98:104-111.
[8] Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl, 2002, 65: 33-38.
[9] Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum, 2001, 44:2862-2869.
[10] Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after stariing tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol, 2001, 45:953-956. |
